TCR2 Therapeutics Inc. (TCRR)
TCR2 Therapeutics Statistics
Share Statistics
TCR2 Therapeutics has 39.26M shares outstanding. The number of shares has increased by 0% in one year.
| Shares Outstanding | 39.26M |
| Shares Change (YoY) | 0% |
| Shares Change (QoQ) | 0% |
| Owned by Institutions (%) | n/a |
| Shares Floating | 26.75M |
| Failed to Deliver (FTD) Shares | 61 |
| FTD / Avg. Volume | 0.02% |
Short Selling Information
| Short Interest | n/a |
| Short % of Shares Out | n/a |
| Short % of Float | n/a |
| Short Ratio (days to cover) | n/a |
Valuation Ratios
The PE ratio is -0.25 and the forward PE ratio is null. TCR2 Therapeutics's PEG ratio is -0.01.
| PE Ratio | -0.25 |
| Forward PE | n/a |
| PS Ratio | 0 |
| Forward PS | n/a |
| PB Ratio | 0.27 |
| P/FCF Ratio | -0.33 |
| PEG Ratio | -0.01 |
Enterprise Valuation
TCR2 Therapeutics has an Enterprise Value (EV) of 59.6M.
| EV / Sales | 0 |
| EV / EBITDA | -0.67 |
| EV / EBIT | -0.59 |
| EV / FCF | -0.51 |
Financial Position
The company has a current ratio of 2.77, with a Debt / Equity ratio of 0.38.
| Current Ratio | 2.77 |
| Quick Ratio | 2.77 |
| Debt / Equity | 0.38 |
| Debt / EBITDA | -0.6 |
| Debt / FCF | -0.46 |
| Interest Coverage | -2.61 |
Financial Efficiency
Return on Equity is -107.78% and Return on Invested Capital is -79.01%.
| Return on Equity | -107.78% |
| Return on Assets | -72.91% |
| Return on Invested Capital | -79.01% |
| Revenue Per Employee | $0 |
| Profits Per Employee | $-2.62M |
| Employee Count | 58 |
| Asset Turnover | 0 |
| Inventory Turnover | n/a |
Taxes
| Income Tax | 261K |
| Effective Tax Rate | -0.17% |
Stock Price Statistics
The stock price has increased by 0% in the last 52 weeks. The beta is 1.93, so TCR2 Therapeutics's price volatility has been higher than the market average.
| Beta | 1.93 |
| 52-Week Price Change | 0% |
| 50-Day Moving Average | 1.69 |
| 200-Day Moving Average | 1.64 |
| Relative Strength Index (RSI) | 27.34 |
| Average Volume (20 Days) | 325.04K |
Income Statement
| Revenue | n/a |
| Gross Profit | 0 |
| Operating Income | -153.5M |
| Net Income | -151.82M |
| EBITDA | -89.62M |
| EBIT | -92.67M |
| Earnings Per Share (EPS) | -3.93 |
Balance Sheet
The company has 32.75M in cash and 53.76M in debt, giving a net cash position of -21.02M.
| Cash & Cash Equivalents | 32.75M |
| Total Debt | 53.76M |
| Net Cash | -21.02M |
| Retained Earnings | -501.34M |
| Total Assets | 151.51M |
| Working Capital | 93.02M |
Cash Flow
In the last 12 months, operating cash flow was -101.46M and capital expenditures -15.45M, giving a free cash flow of -116.91M.
| Operating Cash Flow | -101.46M |
| Capital Expenditures | -15.45M |
| Free Cash Flow | -116.91M |
| FCF Per Share | -3.03 |
Margins
| Gross Margin | n/a |
| Operating Margin | n/a |
| Pretax Margin | n/a |
| Profit Margin | n/a |
| EBITDA Margin | n/a |
| EBIT Margin | n/a |
| FCF Margin | n/a |
Dividends & Yields
TCRR does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Payout Ratio | n/a |
| Earnings Yield | -393.51% |
| FCF Yield | -303.03% |
Analyst Forecast
Currently there are no analyst rating for TCRR.
| Price Target | n/a |
| Price Target Difference | n/a |
| Analyst Consensus | n/a |
| Analyst Count | n/a |
Scores
| Altman Z-Score | -7.19 |
| Piotroski F-Score | 2 |